🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

PetMed shares downgraded to hold, target set on current challenges

EditorNatashya Angelica
Published 07/08/2024, 15:48
PETS
-

On Wednesday, Lake Street Capital Markets revised its stance on shares of PetMed Express (NASDAQ:PETS), downgrading the stock from Buy to Hold and establishing a price target of $3.50. The adjustment reflects concerns over near-term pressures on the company. According to the analyst, PetMed Express is likely to face ongoing challenges due to the uncertain timeline of its business turnaround and broader macroeconomic difficulties.

The firm's new management team is credited with having a clear vision for the future, actively working on brand consolidation, supply chain improvements, customer retention, increased site traffic, marketing refinement, and technology upgrades. These steps are aimed at streamlining operations, fostering growth, and enhancing profitability.

Despite these strategic efforts, the analyst expects the company's financial performance to remain subdued for some time. The management has observed monthly enhancements in average order value and margins, which is considered a positive development. However, the belief is that it will take time for these improvements to significantly impact the company's overall financial health.

The analyst's decision to set the price target to $3.50, matching the after-hours trading price, is based on the perspective that the shares will likely not see substantial movement until there is a clear sign of financial improvement. This price target is seen as a fair reflection of PetMed Express's current valuation, which is noted to be at a historical low.

In other recent news, PetMed Express has reported a 6.6% increase in net sales for the fourth quarter, primarily attributed to the acquisition of PetCareRx. The company has announced strategic initiatives that include brand consolidation, supply chain improvements, and technology platform upgrades.

Leah Solivan, a General Partner at Fuel Capital and founder of TaskRabbit, has been appointed to PetMed Express's Board of Directors, a move seen as strategic during the company's transformational period.

Lake Street Capital Markets has revised its outlook on PetMed Express, reducing the price target from $9 to $7, but maintains a Buy rating. The firm's stance is cautious regarding the company's near-term performance, despite recognizing potential value in PetMed Express's platform and new strategies. Lake Street maintains a positive outlook on the company's prospects, highlighting its ability to attract new customers and grow recurring revenue streams.

PetMed Express is in a strong financial position with $55 million in cash reserves and no debt, providing the necessary capital for its investments. The company is focusing on customer retention and loyalty, with plans to expand its loyalty program. These recent developments underscore PetMed Express's commitment to sustainable growth and operational efficiency.

InvestingPro Insights

With Lake Street Capital Markets downgrading PetMed Express (NASDAQ:PETS), investors are keenly observing the company's financial health and future prospects. Based on real-time data from InvestingPro, PetMed Express holds a market capitalization of approximately $65.98 million.

The company's P/E ratio stands at -29.3, reflecting market skepticism about its earnings potential. However, it's notable that PetMed Express holds more cash than debt on its balance sheet, which could provide some financial flexibility in its turnaround efforts.

InvestingPro Tips highlight that PetMed Express is trading at a low revenue valuation multiple with a price/book ratio of 0.78 in the last twelve months as of Q1 2023. This suggests the stock may be undervalued relative to its assets.

Moreover, despite recent challenges, PetMed Express has maintained dividend payments for 15 consecutive years, signaling a commitment to returning value to shareholders. Yet, it is important to note that the company's price has fallen significantly over the last year, currently trading near its 52-week low, indicating that the market has had a bearish outlook on the stock.

Investors looking for a deeper dive into PetMed Express can find additional InvestingPro Tips by visiting https://www.investing.com/pro/PETS. With a total of 13 tips available, these insights could provide valuable context for those considering an investment in the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.